Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 17/20 | 0.62 |
| ▸ | THRA | P10827 | 16/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105511 | 0.89 | THRB (0.48) | THRBTHRAESR2HTT | |
| SCHEMBL664208 | 0.85 | THRB (0.64) | THRBTHRAESR1ESR2 | |
| SCHEMBL667473 | 0.83 | THRB (0.45) | THRBTHRAALDH1A1HTT | |
| SCHEMBL282002 | 0.83 | THRB (0.67) | THRBTHRA | |
| SCHEMBL25773018 | 0.83 | THRB (0.71) | THRBTHRAESR1ESR2LMNA | |
| SCHEMBL328377 | 0.83 | THRB (0.67) | THRBTHRAESR1ESR2 | |
| SCHEMBL13381717 | 0.82 | THRB (0.60) | THRBTHRA | |
| SCHEMBL667308 | 0.81 | THRB (0.69) | THRBTHRA | |
| SCHEMBL27666369 | 0.81 | THRB (0.61) | THRBTHRA | |
| SCHEMBL1457668 | 0.80 | THRB (0.67) | THRBTHRAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010093601-A1 | NOVEL SULFONIC ACID-CONTAINING THYROMIMETICS, AND METHODS FOR THEIR USE | METABASIS THERAPEUTICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | THRB 1/4885THRA 3/4885ESR1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.